Bourgeon Capital Management LLC lifted its position in shares of iShares Biotechnology ETF (NASDAQ:IBB – Free Report) by 7.8% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 4,218 shares of the financial services provider’s stock after purchasing an additional 305 shares during the quarter. Bourgeon Capital Management LLC’s holdings in iShares Biotechnology ETF were worth $558,000 at the end of the most recent reporting period.
Other institutional investors also recently modified their holdings of the company. Security National Bank of SO Dak lifted its holdings in shares of iShares Biotechnology ETF by 0.7% in the second quarter. Security National Bank of SO Dak now owns 10,461 shares of the financial services provider’s stock valued at $1,436,000 after purchasing an additional 75 shares in the last quarter. SPC Financial Inc. raised its position in iShares Biotechnology ETF by 2.4% in the 3rd quarter. SPC Financial Inc. now owns 3,265 shares of the financial services provider’s stock valued at $475,000 after buying an additional 75 shares during the last quarter. Werba Rubin Papier Wealth Management lifted its stake in iShares Biotechnology ETF by 2.7% during the 3rd quarter. Werba Rubin Papier Wealth Management now owns 2,918 shares of the financial services provider’s stock valued at $425,000 after acquiring an additional 76 shares in the last quarter. Capital Investment Advisors LLC boosted its holdings in iShares Biotechnology ETF by 1.0% during the 4th quarter. Capital Investment Advisors LLC now owns 10,449 shares of the financial services provider’s stock worth $1,381,000 after acquiring an additional 99 shares during the last quarter. Finally, Prairie Wealth Advisors Inc. grew its stake in shares of iShares Biotechnology ETF by 6.0% in the 2nd quarter. Prairie Wealth Advisors Inc. now owns 1,765 shares of the financial services provider’s stock worth $242,000 after acquiring an additional 100 shares in the last quarter. 62.45% of the stock is owned by institutional investors and hedge funds.
iShares Biotechnology ETF Price Performance
IBB opened at $136.10 on Wednesday. iShares Biotechnology ETF has a fifty-two week low of $123.60 and a fifty-two week high of $150.57. The company’s 50-day moving average is $136.15 and its 200 day moving average is $141.84.
iShares Biotechnology ETF Cuts Dividend
iShares Biotechnology ETF Company Profile
iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.
Featured Articles
- Five stocks we like better than iShares Biotechnology ETF
- What Investors Need to Know About Upcoming IPOs
- SAP’s Strong Momentum: A Bullish Setup for Investors
- What is the S&P/TSX Index?
- BlackRock Breaks Records: Why the Stock Still Has Room to Run
- P/E Ratio Calculation: How to Assess Stocks
- Duke vs. NRG: Which Energy Stock Will Power Higher Gains?
Want to see what other hedge funds are holding IBB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for iShares Biotechnology ETF (NASDAQ:IBB – Free Report).
Receive News & Ratings for iShares Biotechnology ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iShares Biotechnology ETF and related companies with MarketBeat.com's FREE daily email newsletter.